Dr. Jim Hu - The Benefits of Robotic Surgery
To make an appointment with Dr. Jim Hu at the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.
In this video, Dr. Hu speaks about the benefits of robotic surgery as it compares to traditional open surgery for the treatment of urologic cancers, and some of the features inherent to the robot and process that allow for these improved outcomes.
Dr. Jim Hu - Prostate Cancer Research, PSA Screening & HIFU
To make an appointment with Dr. Jim Hu at the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.
In this video, Dr. Hu discusses some of his research endeavors as a prostate cancer physician-scientist at Weill Cornell Medicine, including examinations of PSA screening guidelines and the High Intensity Focused Ultrasound (HIFU) procedure.
Dr. Jim Hu - History & Future of Robotic Surgery in Urology
To make an appointment with Dr. Jim Hu at the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.
In this video, Dr. Hu discusses the history of robotic surgery as it has been widely accepted in the field of urology and within medicine generally. Within urology, robotic surgery was first used to treat prostate cancer, but has now been used to treat many different types of cancer and benign disease.
Dr. Jim Hu - Advances in Urology Are Made Between Fields
To make an appointment with Dr. Jim Hu at the LeFrak Center for Robotic Surgery at NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.
In this video, Dr. Hu speaks about some of his key collaborations at Weill Cornell Medicine that have lead to urologic oncology research developments to improve patient care.
Active surveillance, physician–patient communication may redefine role of PSA testing
In a 2014 modeling study published in Cancer, Gulati and colleagues predicted that if PSA screening continued at its current rate, 710,000 to 1.1 million men would be overdiagnosed between 2013 and 2025, but that 36,000 to 57,000 prostate cancer deaths would be prevented during that period.
Prostate Cancer Partial Gland Ablation - Webinar with Dr. Jim C. Hu
Jim C. Hu, M.D., M.P.H. discusses various minimally-invasive and non-surgical treatment options under the umbrella term of partial gland ablation.
Dr. Hu speaks about techniques & practical outcomes of various partial ablation procedures performed for men with prostate cancer, most notably the High Intensity Focused Ultrasound (HIFU) procedure, which is performed at Weill Cornell Medicine.
Dr. Hu - Elevated PSA & MRI Targeted Biopsy - Prostate Cancer Webinar
Jim C. Hu, MD, MPH talks prostate cancer, evaluation of elevated PSA, targeted sampling of prostate tissue using MRI-Ultrasound fusion guided biopsy, as well as prostate MRI, PIRADS scoring and biomarkers.
Incidence of Metastatic Prostate Cancer in Older Men Increases Following Drop in PSA Screening
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.
Incidence of metastatic prostate cancer has increased among older men as PSA screening declines (With Dr. Jim C. Hu)
The incidence of metastatic prostate cancer appears to be rising in men aged 75 years or older, according to results of a SEER analysis published in JAMA Oncology.
This increase may be linked to the U.S. Preventive Services Task Force (USPSTF) 2008 recommendation against routine PSA screenings in men aged 75 years or older and the 2012 recommendation against routine PSA screening regardless of age.
